Generic Name: cabotegravir

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Integrase Inhibitors

Company: ViiV Healthcare

Approval Status: Experimental

Generic Version Available: No

Experimental Code: N/A


Drug Indication

Cabotegravir is a medication for HIV treatment. Vocabria pills are approved for use with Edurant (rilpivirine) as a short-term treatment regimen. Vocabria has not yet been reviewed for inclusion in the DHHS list of recommended medications for HIV treatment or prevention.

Cabenuva is a long-acting treatment regimen that consists of extended-release cabotegravir and rilpivirine injections. Long-acting injectable cabotegravir is also being studied for pre-exposure prophylaxis (PrEP). 


General Info

Vocabria is an integrase inhibitor antiretroviral medication. It is used with Edurant (rilpivirine) for short-term HIV treatment. The pills are used as a lead-in regimen for people who want to switch to Cabenuva injections and may be substitute if someone has to miss a planned injection appointment.


Dosage

Dosing Info:

Vocabria pills are taken once daily, in combination with once-daily Edurant pills, as a oral lead-in regimen for a month before switching to Cabenuva injections.


Side Effects

The most commonly reported side effects are headache, nausea, abnormal dreams, anxiety and insomnia.


Drug Interactions

For a review of drug interactions, including prescription and over-the-counter medications and supplements that should not be taken with Vocabria or may require dose adjustments, consult the Vocabria package insert.


Other Info

https://www.poz.com/article/viiv-applies-approval-first-longacting-injectable-hiv-regimen


For More Info: https://viivhealthcare.com/en-gb/our-medicines/vocabria/

Patient Assistance Program Info: https://www.viivconnect.com/patient-assistance-program/

Last Reviewed: January 24, 2021